A unique approach to helminthiasis treatment

Our approach at STOP2030 is to combine two existing drugs into a single tablet that allows a more efficient and affordable treatment of helminthic infections.These two compounds are albendazole and ivermectin, both anthelmintics already licensed and widely-used around the world. Their mechanisms of action are different, resulting in a broader efficacy and minimising the risk of resistances. This combination has been proved safe and effective by our previous clinical trials, and is in the last stages of development before regulatory approval.

The development of a new drug is not enough to stop soil-transmitted helminths (STH). Other considerations like ensuring affordable pricing, sustainable financing,and planning the best implementation strategy with key stakeholders are essential for long-term success. In order to make the new treatment a real option, including for the poorest and most neglected communities, we also prepare the regulatory and supply pathways for implementation. By engaging policy and decision makers internationally and in governments, we aim to support the future use of this new treatment and make real strides to control the unbearable burden of intestinal worms.

Previous strategies have been insufficient to reach the World Health Organisation’s objectives in STH control. In their latest roadmap for 2030, they aim to achieve and maintain elimination of STH-associated morbidity in children (<2% prevalence). Given the concerns in current control strategies using benzimidazoles (albendazole or mebendazole), our new combined approach can work as a solution soon ready for scale up in countries.